Providing stock analysis for investors of the Canadian junior markets
Cardiol Therapeutics (TSX: CRDL) has seen a series of insider buys made in recent days, which follows the company seeing success under phase two trials announced in November. A total of four insiders have been in the market this week buying shares, including the firms chief executive, as well as its chief financial officer.
Read more
In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions.
Read more
Cardiol Therapeutics (TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug candidate. The drug is currently going through clinical trials for use in the treatment of heart disease, specifically recurrent pericarditis and acute myocarditis.
Read more
Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by Shoppers, which is a subsidiary
Read more
Cardiol Therapeutics (TSX: CRDL; OTCMKTS: CRTPF) announced this morning that it has qualified to trade on the OTCQX Best Market,
Read more
With a heavy focus on cannabinoids, Cardiol Therapeutics (TSX: CRDL) is not your typical cannabis stock. Rather than focusing on
Read more